From stratification to therapy
Metabolic pathways rather than organs
First universal digital twin in oncology paving the way for effective oncology based on pan-cancer stratification
More patients can benefit from your therapy
Pharmaceuticals companies : You have an anti-cancer targeted molecule in clinical phase 1, let’s work together to define the inclusion and exclusion criteria for phases 2 and 3, enabling your molecules to be brought to market.
Biotech companies : You want to develop a pan cancer drug. Let’s work together to find the good target
Our product range
Clinical trial optimization
Companion diagnostic
Stratification
Repositioning and repurposing of targeted therapies
New target pan cancer
They support us
- UPCité
- CNRS
- INCA
- Erganéo
- Paris Biotech Santé
- France 2030